104 related articles for article (PubMed ID: 12350503)
1. Detection of a non-Hodgkin's lymphoma by capromab pendetide scintigraphy (ProstaScint) in a patient with prostate carcinoma.
Zanzi I; Stark R
Urology; 2002 Sep; 60(3):514. PubMed ID: 12350503
[TBL] [Abstract][Full Text] [Related]
2. Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer.
Petronis JD; Regan F; Lin K
Clin Nucl Med; 1998 Oct; 23(10):672-7. PubMed ID: 9790041
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy.
Raj GV; Partin AW; Polascik TJ
Cancer; 2002 Feb; 94(4):987-96. PubMed ID: 11920467
[TBL] [Abstract][Full Text] [Related]
4. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy.
Fang DX; Stock RG; Stone NN; Krynyckyi BR; Kim CK; Machac J
Tech Urol; 2000 Jun; 6(2):146-50. PubMed ID: 10798816
[TBL] [Abstract][Full Text] [Related]
5. Capromab Pendetide imaging of prostate cancer.
Haseman MK; Rosenthal SA; Polascik TJ
Cancer Biother Radiopharm; 2000 Apr; 15(2):131-40. PubMed ID: 10803318
[TBL] [Abstract][Full Text] [Related]
6. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint Study Group.
Kahn D; Williams RD; Manyak MJ; Haseman MK; Seldin DW; Libertino JA; Maguire RT
J Urol; 1998 Jun; 159(6):2041-6; discussion 2046-7. PubMed ID: 9598514
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer.
Anderson RS; Eifert B; Tartt S; King P
Urology; 2000 Oct; 56(4):669. PubMed ID: 11018634
[TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer.
Nagda SN; Mohideen N; Lo SS; Khan U; Dillehay G; Wagner R; Campbell S; Flanigan R
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(3):834-40. PubMed ID: 17293236
[TBL] [Abstract][Full Text] [Related]
9. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer.
Rosenthal SA; Haseman MK; Polascik TJ
Tech Urol; 2001 Mar; 7(1):27-37. PubMed ID: 11272670
[TBL] [Abstract][Full Text] [Related]
10. Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy.
Kahn D; Williams RD; Haseman MK; Reed NL; Miller SJ; Gerstbrein J
J Clin Oncol; 1998 Jan; 16(1):284-9. PubMed ID: 9440754
[TBL] [Abstract][Full Text] [Related]
11. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers.
Sodee DB; Malguria N; Faulhaber P; Resnick MI; Albert J; Bakale G
Urology; 2000 Dec; 56(6):988-93. PubMed ID: 11113745
[TBL] [Abstract][Full Text] [Related]
12. Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer.
Koontz BF; Mouraviev V; Johnson JL; Mayes J; Chen SH; Wong TZ; Anscher MS; Sun L; Moul J; Polascik TJ
Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):358-61. PubMed ID: 18164863
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Kahn D; Austin JC; Maguire RT; Miller SJ; Gerstbrein J; Williams RD
Cancer Biother Radiopharm; 1999 Apr; 14(2):99-111. PubMed ID: 10850293
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
[TBL] [Abstract][Full Text] [Related]
15. Possible false-positive metastatic prostate cancer on an In-111 capromab pendetide scan as a result of a pelvic kidney.
Valliappan S; Joyce JM; Myers DT
Clin Nucl Med; 1999 Dec; 24(12):984-5. PubMed ID: 10595486
[No Abstract] [Full Text] [Related]
16. Comparison of clinical staging algorithms and 111indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.
Polascik TJ; Manyak MJ; Haseman MK; Gurganus RT; Rogers B; Maguire RT; Partin AW
Cancer; 1999 Apr; 85(7):1586-92. PubMed ID: 10193950
[TBL] [Abstract][Full Text] [Related]
17. Detection of Recurrent Non-Hodgkin Lymphoma on In-111 Capromab Pendetide Imaging.
Franc BL; Lin H
Clin Nucl Med; 2015 Jul; 40(7):585-8. PubMed ID: 25899589
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer abdominal metastases detected with indium-111 capromab pendetide.
Hinkle GH; Burgers JK; Olsen JO; Williams BS; Lamatrice RA; Barth RF; Rogers B; Maguire RT
J Nucl Med; 1998 Apr; 39(4):650-2. PubMed ID: 9544673
[TBL] [Abstract][Full Text] [Related]
19. The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy.
Wilkinson S; Chodak G
J Urol; 2004 Jul; 172(1):133-6. PubMed ID: 15201753
[TBL] [Abstract][Full Text] [Related]
20. The impact of a negative (111)indium-capromab pendetide scan before salvage radiotherapy.
Proaño JM; Sodee DB; Resnick MI; Einstein DB
J Urol; 2006 May; 175(5):1668-72. PubMed ID: 16600726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
